Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

The department focuses on personalized oncology to improve outcomes for patients with Metastatic Non-small Cell Lung Cancer that express high PD‑L1 levels.

• Evaluation of pembrolizumab combined with sacituzumab govitecan versus pembrolizumab alone
• Assessment of progression‑free survival using RECIST 1.1 criteria
• Measurement of overall survival benefits
• Monitoring safety and tolerability of the combination regimen

Research is conducted at the Deutsches Krebsforschungszentrum in Mannheim, leveraging its expertise in lung‑cancer biology to test new immunotherapy strategies.

Studies aim to address the unmet need in patients with advanced or metastatic solid tumors harboring a KRAS G12D mutation.

• Investigation of the safety profile of GDC‑7035 as a single agent
• Exploration of combination approaches with other anti‑cancer therapies
• Characterization of pharmacokinetic properties and drug exposure
• Evaluation of molecular response and activity in KRAS‑mutated tumors

The trial series is carried out by the Abteilung Personalisierte Onkologie mit Schwerpunkt Lungenkarzinom at the DKFZ, integrating precision medicine tools to guide treatment decisions.